NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PreludeDx

PreludeDx

Private
Laguna Hills, CaliforniaHealthcare & Life Scienceshttps://preludedx.com/

Last Round

VC Round

Mar 22, 2022

Total Funding Raised

$3.51M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PreludeDx is a biotechnology company that develops and provides precision diagnostic tests for early-stage breast cancer.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

precision medicinemolecular diagnosticsbreast cancer diagnosticsDCISionRTprognostic testingoncology diagnosticscancer biomarkerliquid biopsyspatial proteomicsRNA sequencingclinical decision supportAI diagnosticstreatment de-escalationpersonalized medicinemedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PreludeDx Comps

Public and private peers based on sector, stage, and business model.

PreludeDx comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

PreludeDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 22, 2022
StrategicJul 19, 2021
GrantJan 1, 2014
Series AJul 27, 2011

Key People

Founding team and executive leadership

Dan Forche

President And CEO

Executive Team

Andy Wade

Chief Financial Officer

Executive Team

PreludeDx Investors

Notable investors and investment history

PreludeDx investors
InvestorRounds
National Cancer InstituteGrant
Fjord VenturesVC Round, Series A
Evidity Health CapitalVC Round
BlueStone Venture PartnersVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    Received designation for AidaBreast test for early-stage invasive breast cancer.

  • Jan 22, 2026

    MiMi Reyes appointed as new SVP of Operations.

PreludeDx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PreludeDx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PreludeDx's valuation, stock price, and market status.

Firmographic Details

HeadquartersLaguna Hills, California
Employee Range94
Year Founded2009
Last FundingMar 22, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.